Pharming Group N.V. provided earnings guidance for the remainder of 2020. The company expects, subject to progression of the COVID-19 pandemic in the US; continued growth in revenues from sales of RUCONEST®, compared to the first half of 2020, mainly driven by the US and expanded European operations. The company expects maintenance of positive net earnings during the year.